These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31856838)

  • 1. Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study.
    Leaker BR; Singh D; Lindgren S; Almqvist G; Eriksson L; Young B; O'Connor B
    Respir Res; 2019 Dec; 20(1):288. PubMed ID: 31856838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
    Siddall H; Quint D; Pandya H; Powley W; Shabbir S; Hohlfeld JM; Singh D; Lee L
    PLoS One; 2020; 15(11):e0240964. PubMed ID: 33166307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study.
    Greiff L; Ahlström-Emanuelsson C; Alenäs M; Almqvist G; Andersson M; Cervin A; Dolata J; Lindgren S; Mårtensson A; Young B; Widegren H
    Inflamm Res; 2015 Nov; 64(11):903-15. PubMed ID: 26342289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis.
    Greiff L; Cervin A; Ahlström-Emanuelsson C; Almqvist G; Andersson M; Dolata J; Eriksson L; Högestätt E; Källén A; Norlén P; Sjölin IL; Widegren H
    Respir Res; 2012 Jun; 13(1):53. PubMed ID: 22726593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approach.
    Bell J; Dymond M; Biffen M; Delaney S; Keeling D; Zhang H; Robinson I
    Toxicol Appl Pharmacol; 2018 Jan; 338():9-19. PubMed ID: 29122671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial.
    Beeh KM; Beier J; Meyer M; Buhl R; Zahlten R; Wolff G
    Pulm Pharmacol Ther; 2006; 19(4):233-41. PubMed ID: 16140027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
    Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
    Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
    Wenzel S; Wilbraham D; Fuller R; Getz EB; Longphre M
    Lancet; 2007 Oct; 370(9596):1422-31. PubMed ID: 17950857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses.
    Pizzichini MM; Kidney JC; Wong BJ; Morris MM; Efthimiadis A; Dolovich J; Hargreave FE
    Eur Respir J; 1996 Mar; 9(3):449-55. PubMed ID: 8730003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
    Krug N; Hohlfeld JM; Kirsten AM; Kornmann O; Beeh KM; Kappeler D; Korn S; Ignatenko S; Timmer W; Rogon C; Zeitvogel J; Zhang N; Bille J; Homburg U; Turowska A; Bachert C; Werfel T; Buhl R; Renz J; Garn H; Renz H
    N Engl J Med; 2015 May; 372(21):1987-95. PubMed ID: 25981191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.
    Leaker BR; Barnes PJ; O'Connor BJ; Ali FY; Tam P; Neville J; Mackenzie LF; MacRury T
    Clin Exp Allergy; 2014 Sep; 44(9):1146-53. PubMed ID: 25040039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
    Gauvreau GM; Hohlfeld JM; FitzGerald JM; Boulet LP; Cockcroft DW; Davis BE; Korn S; Kornmann O; Leigh R; Mayers I; Watz H; Grant SS; Jain M; Cabanski M; Pertel PE; Jones I; Lecot JR; Cao H; O'Byrne PM
    Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36822634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848.
    Delaney S; Biffen M; Maltby J; Bell J; Asimus S; Aggarwal A; Kraan M; Keeling D
    BMJ Open Respir Res; 2016; 3(1):e000113. PubMed ID: 26933507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
    Beeh KM; Kanniess F; Wagner F; Schilder C; Naudts I; Hammann-Haenni A; Willers J; Stocker H; Mueller P; Bachmann MF; Renner WA
    J Allergy Clin Immunol; 2013 Mar; 131(3):866-74. PubMed ID: 23384679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma.
    Diamant Z; Grootendorst DC; Veselic-Charvat M; Timmers MC; De Smet M; Leff JA; Seidenberg BC; Zwinderman AH; Peszek I; Sterk PJ
    Clin Exp Allergy; 1999 Jan; 29(1):42-51. PubMed ID: 10051701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
    Diamant Z; Timmers MC; van der Veen H; Friedman BS; De Smet M; Depré M; Hilliard D; Bel EH; Sterk PJ
    J Allergy Clin Immunol; 1995 Jan; 95(1 Pt 1):42-51. PubMed ID: 7822663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a CCR3 inhibitor, AXP1275, on allergen-induced airway responses in adults with mild-to-moderate atopic asthma.
    Gauvreau GM; FitzGerald JM; Boulet LP; Watson RM; Hui L; Villineuve H; Scime TX; Schlatman AR; Obminski C; Kum J; Boehme S; Ly TW; Bacon KB; O'Byrne PM
    Clin Exp Allergy; 2018 Apr; 48(4):445-451. PubMed ID: 29423947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma.
    Boulet LP; Gauvreau GM; Cockcroft DW; Davis B; Vachon L; Cormier Y; O'Byrne PM
    Can Respir J; 2015; 22(4):230-4. PubMed ID: 26252534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma.
    Boot JD; de Haas S; Tarasevych S; Roy C; Wang L; Amin D; Cohen J; Sterk PJ; Miller B; Paccaly A; Burggraaf J; Cohen AF; Diamant Z
    Am J Respir Crit Care Med; 2007 Mar; 175(5):450-7. PubMed ID: 17170385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers.
    Parameswaran K; Inman MD; Watson RM; Morris MM; Efthimiadis A; Ventresca PG; Lam R; O'Byrne PM; Hargreave FE
    Can Respir J; 2000; 7(4):313-9. PubMed ID: 10980457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.